Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab – a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)

Introduction Combined vascular endothelial growth factor/programmed death-ligand 1 blockade through atezolizumab/bevacizumab (A/B) is the current standard of care in advanced hepatocellular carcinoma (HCC). A/B substantially improved objective response rates compared with tyrosine kinase inhibitor s...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Patrick Michl, Peter Schirmacher, Andreas Teufel, Christoph Springfeld, Dirk Jäger, Anastasia Tsakmaklis, Anja Sander, Arne Kandulski, Conrad Rauber, Maria Paula Roberti, Maria JGT Vehreschild, Thomas Ettrich, Leonie Jochheim, Pavlos Missios, Raphael Mohr, Alexander Reichart, Dirk T Waldschmidt, Lukas D Sauer, Michael T Dill
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMJ Publishing Group 2025-09-01
Ráidu:	BMJ Open
Liŋkkat:	https://bmjopen.bmj.com/content/15/9/e097802.full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!